overall survival

Yervoy (ipilimumab) Fails to Extend Survival in Men with mCRP Who Failed Chemo

Some bad news was reported today. Results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in men with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel showed no increase in overall survival. Yervoy is an immunotherapy which [...]

By Malecare|2017-10-19T10:49:29-04:00September 12th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ipilimumab, Uncategorized, Understanding APC, Yervoy|0 Comments

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

By Malecare|2020-02-04T11:49:50-05:00September 4th, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, biomarkers, bisphosphonates, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Hormone Therapy, Research, Start A Cure, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Previous 56